sameAs
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsA Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerStudy to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic AdenocarcinomaRucaparib Hepatic Impairment Study in Patients With a Solid TumorA Study of Rucaparib in Japanese Patients With a Previously-treated Solid TumorA Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
P859
description
small pharmaceutical company
@en
name
Clovis Oncology
@en
type
label
Clovis Oncology
@en
altLabel
Clovis Oncology, Inc.
@en
prefLabel
Clovis Oncology
@en
P1454
P159
P213
0000 0004 0495 2551
P2427
grid.476183.f
P3500
P414
P571
2009-01-01T00:00:00Z